Disease relevance of MG 13608

• Acute toxicity and effect on respiratory tract excretion were evaluated for domiodol and for each isomer: no significant differences were found [1].
• Thirty children (25 males, five females), mean age 9.33 +/- 2.57 years, with acute infectious pulmonary diseases or acute flare-ups of chronic bronchitis, were randomly treated with either domiodol or placebo [2].

High impact information on MG 13608

• Domiodol (Mucolitico Maggioni, CAS 61869-07-6), an organic iodinated mucolytic agent, was given at the dosage of 60 mg t.i.d. to 20 patients in the post-operative period after laryngectomy (average 2 weeks in hospital and 4 months follow-up at home) [3].
• Spirometric measures of vital capacity and peak expiratory flow rate were also improved in patients given domiodol compared with placebo [2].
• Cis and trans isomers of 2-iodomethyl-4-hydroxymethyl-1,3-dioxolane (domiodol, MG 13 608) were separated by preparative GLC and prepared on a larger scale by previous resolution of an intermediate [1].
• In addition, oral domiodol (50 and 100 mg/kg) significantly reduced the viscosity of sputum collected quantitatively from rabbits with subacute bronchitis induced by long-term exposure to SO2 gas; the percentage decrease in viscosity was statistically correlated with the content of dry matter, protein and polysaccharides in the sputum [4].
• Changes of T3 levels and a slight increase in thyroid weight accompanied by minimal histological alterations were observed in rats given high doses of domiodol [4].

Analytical, diagnostic and therapeutic context of MG 13608

• Mucolytic effects of domiodol in tracheostomized patients after total laryngectomy. Double-blind, placebo-controlled, randomized pilot study with four-month follow-up [3].

References